Get the Daily Brief
Latest Biotech News
Biotech financing and IPO pipelines
Avalyn Pharma moved closer to the public markets by targeting an IPO raise of about $182 million, aiming to take inhaled reformulations of approved respiratory medicines into late-stage clinical...
Gene therapy momentum: hearing loss and beyond
Beyond Otarmeni’s FDA clearance, the broader gene-therapy ecosystem continued to show momentum through manufacturing and delivery partnerships. Andelyn Biosciences and ENCell, both CMOs, announced...
Clinical data and early-phase oncology signals
At AACR 2026, multiple early-phase studies reported clinical activity across targeted and antibody-drug conjugate approaches in difficult solid-tumor settings. In one readout, zoldonrasib—an...
Biopharma partnerships and corporate transactions
CNS-focused biotech Tortugas raised substantial venture capital to advance a portfolio of neurology compounds sourced through licensing from Eisai and Hansoh. The disclosed funding totaled $106...
Retinal therapies: Ray’s Series B and late-stage clinical push
Ray Therapeutics closed a $125 million Series B to advance its retinal gene therapy pipeline, with plans for late-stage execution behind its lead optogenetic program RTx-015 for retinitis...
Diagnostics and regulatory-access acceleration
The FDA and CMS announced a new RAPID coverage pathway intended to reduce the time between FDA authorization and Medicare coverage decisions for breakthrough medical devices. Under RAPID, eligible...
AI in healthcare operations and precision medicine workflows
Tempus’ USC partnership capped another week of AI-enabled clinical infrastructure growth, but a separate development highlighted the remaining evidence gap for healthcare AI outcomes. Researchers...
Biotech policy and transparency around FDA complete response letters
A citizen petition filed by an unnamed pharma company seeks changes to the FDA’s policy of publishing complete response letters for drugs and biologics that fail to gain approval. The petition...
Regulatory approvals and EU follow-ons
Europe moved to close the gap left by an FDA rejection of Sanofi’s multiple sclerosis therapy tolebrutinib. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)...
Gene therapy and cellular therapy milestones
Kyverna Therapeutics disclosed positive registrational Phase II results for mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome, including rapid improvements by week 16 and a high...
Oncology pipeline signals at major meetings
Pancreatic cancer data kept dominating AACR conversations as Revolution Medicines reported updated clinical performance for daraxonrasib, including first-line results and continued signs of deep...
Diagnostic innovation, commercialization, and partnerships
ClearNote Health advanced its pancreatic cancer early-detection franchise with updated assay performance presented at AACR. The company said adding a glycan biomarker (CA19-9) to its core...
Financing and capital-market moves
Ray Therapeutics secured $125 million in a Series B financing to fund late-stage clinical development and commercial readiness for its mutation-agnostic retinal gene therapy program RTx-015 in...
Manufacturing capacity and supply-chain scaling
IDT expanded manufacturing capacity at its Coralville, Iowa facility to increase oligonucleotide synthesis output more than threefold. The expansion includes installation of additional...
M&A and partnership dealflow in biotech
QuidelOrtho completed its acquisition of Lex Diagnostics for about $100 million in cash, bringing forward a CLIA-cleared Velo point-of-care molecular diagnostic system. The closing was triggered...
AI adoption and evidence gaps in healthcare
A new analysis in Nature Medicine raised a caution flag for healthcare AI tools: accuracy does not automatically translate into better patient outcomes. The paper highlighted that many widely...
Clinical trial progress and endpoints in rare and high-need settings
A first-in-human clinical trial for a prion disease candidate began enrolling patients, marking a milestone for a fatal neurodegenerative area with limited options. The Phase 1 study will evaluate...
Biopharma manufacturing automation and CGT quality control
CGT industry quality control remains constrained by viral testing challenges, according to a new analysis noting that raw material testing will likely stay central because inactivation and removal...
FDA approval—first gene therapy under new priority voucher for hearing loss
Regeneron’s gene therapy Otarmeni (lunsotogene parvec) won U.S. FDA approval for a rare inherited form of hearing loss caused by variants in the otoferlin gene. The approval marks the first...
Gene editing—base editing corrects hard-to-treat CFTR splicing mutation in cell models
A new cell-model study reports functional correction of the “untreatable” cystic fibrosis mutation 1717-1G>A using CRISPR base editing. Researchers from the University of Trento and collaborators...